CEO of the Year, Round 2: Arena Pharmaceuticals vs. Regions Financial

Following eight straight weeks of profiling top-notch CEOs, and the first week of actual community voting, it's time to unveil which four CEOs are moving onto the quarterfinals and still have a shot at being named the best CEO in 2012.

The methodology behind the voting is simple. Similar to an NCAA-style basketball bracket, the eight CEOs were pitted into four matchups last week that the community had one week to vote on. This week we're releasing the results of the previous week's voting, and the remaining four CEOs are again going to be bracketed for voting. Voting will continue over the next two weeks until we have a winner, which will be unveiled at the beginning of December.

As you can see, the ball really is in your court and you do have a say in who merits the coveted title of The Motley Fool's chosen CEO of the year. Below the voting bracket I've included a recap of last week's voting, as well as a quick synopsis of this week's matchup; however, I encourage you to revisit the nomination article for a more complete explanation of why that particular CEO was nominated for this award:

Last week's recap:

  • Arena Pharmaceuticals (Nasdaq: ARNA  ) crushes Apple (Nasdaq: AAPL  ) : This high-profile matchup wasn't anywhere near as close as originally anticipated. By a margin of 76% to 24%, community members have chosen to send Arena's Jack Lief onto the next round. Perhaps Apple's weak Christmas-quarter guidance and the possibility that the iPad Mini may cannibalize its tablet margins had something to do with the community's lack of support for Apple's Tim Cook?
  • Lumbers Liquidators (NYSE: LL  ) mercy-rules Gap (NYSE: GPS  ) : It wasn't Ronald Reagan vs. Walter Mondale, but by a vote of 92% to 8% it was a landslide in every sense of the word for Lumber Liquidators' Robert Lynch. Not even Gap's 66% jump in net income and boosted full-year forecast could save CEO Glenn Murphy from securing just a fraction of community members' votes.
  • Whole Foods Market (Nasdaq: WFM  ) slices and dices Lions Gate Entertainment (NYSE: LGF  ) : Oddly enough, this matchup received as many votes as nearly all other matchups combined! Unfortunately for Jon Feltheimer and Lions Gate, a ridiculously impressive debut for its latest Twilight movie went for naught as Whole Foods and its co-CEOs John Mackey and Walter Robb advanced by a score of 71% to 29%.
  • Regions Financial (NYSE: RF  ) edges out Silver Wheaton (NYSE: SLW  ) : In what was by far the closest matchup of the four, Regions Financial's Grayson Hall sneaked past Silver Wheaton's Randy Smallwood by a vote of 53% to 47%. Either CEO would be perfectly deserving of moving onto the second round, but it appears Hall will be getting the opportunity per our community members.

Semifinal matchup: Arena Pharmaceuticals vs. Regions Financial
This matchup will pit two very different companies and CEOs against each other to see which one has the pill to cure investors' ills. On one hand, Arena Pharmaceuticals' Jack Lief is an innovator who's led his company to develop what could very well become the first internationally approved anti-obesity drug in Belviq. On the other hand we have Regions Financial's Grayson Hall, who has used traditional banking methods to reinvigorate profits, strengthen his bank's balance sheet, and pay off its entire $3.5 billion in TARP loan obligations. Which pill would you take? That's up to you!

Check back for results
Be sure to check out the other best CEO semifinal matchup at the following link, and check back next week, when we unveil the results and highlight the final round of voting to help determine who is The Motley Fool's choice for best CEO of 2012.

Can Arena Pharmaceuticals do any wrong? Find out the full story with both the opportunities and threats facing Arena from our top biotech analysts by getting your copy of our latest premium research report on Arena. Complete with a year of regular updates, this report will give you the tools you need to make smart long-term investing decisions. Click here to learn more.


Read/Post Comments (1) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 21, 2012, at 9:30 AM, Blindnomore wrote:

    Sure is funny how one of the picks for CEO of the year here is Jack Lief of Arena pharma because looking to the right side shows the rating ARNA has gotten in the CAPS community. Two stars. Hardly a rating worthy of a CEO of the years company. I guess most here have neglected to update their rating or they are still of those diehard stoneheaded fools shorting ARNA. Why, I just can not fathom. If you are, and you are still clinging to that lie about tumors in rats and heart valvulopathy, you might want to actually do some research instead of following the loudest schills running themselves into the ground trying to get this stock back down under $5 or $6 per share. Won't happen, not a chance. Cover before you lose everything.

Add your comment.

DocumentId: 2122442, ~/Articles/ArticleHandler.aspx, 4/21/2014 8:47:30 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement